| Name | Title | Contact Details |
|---|
Danube Pharmaeuticals, Inc., is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Memorial Hospital is a proud part of University of Colorado Health, recognized as a national leader in quality and research. At the local level, Memorial provides a comprehensive list of inpatient and outpatient services at two hospitals and multiple outpatient locations. Memorial provides state-of-the-art, compassionate care in fields such as cardiology, neurology and oncology.
Making an impact on rare and serious skin and connective tissue diseases Fibrocell Science is at the forefront of the exciting and promising field of personalized biologics. By extracting cells from skin to create localized therapies that are compatible with the unique biology of each patient, personalized biologics bring a transformational approach to drug development. It is Fibrocell’s scientific leadership and legacy in cultivating and harnessing autologous fibroblast cells that fuels its personalized biologics approach. Fibrocell’s proprietary technology uses a person’s own fibroblast cells – with or without genetic modification – to target localized treatment of rare and serious skin and connective tissue diseases.
Health Quality Council of Alberta is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.